[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Celldex Therapeutics director Keith L. Brownlie received a grant of 26,000 stock options as part of his compensation. These non-qualified options allow him to buy Celldex common stock at an exercise price of $34.09 per share, under the company’s 2021 Omnibus Equity Incentive Plan.

The options become exercisable starting on June 25, 2027 and expire on June 25, 2036. Following this award, Brownlie is reported as holding 26,000 derivative securities (options) of this type.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brownlie Keith L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	26,000	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 26,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 26,000 options Exercise price: $34.09 per share Underlying shares: 26,000 shares +3 more

6 metrics

Option grant size 26,000 options Non-qualified stock option grant to director on June 25, 2026

Exercise price $34.09 per share Strike price for newly granted options

Underlying shares 26,000 shares Common stock underlying the option grant

Options after grant 26,000 derivative securities Total reported holdings of this option type following transaction

Exercise start date June 25, 2027 Date options become exercisable

Expiration date June 25, 2036 Date options expire if not exercised

Key Terms

Non-Qualified Stock Option (right to buy), 2021 Omnibus Equity Incentive Plan, Grant, award, or other acquisition

3 terms

Non-Qualified Stock Option (right to buy) financial

"security_title: Non-Qualified Stock Option (right to buy)"

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:09 PM Accepted by SEC EDGAR 06/29/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brownlie Keith L

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		26,000		06/25/2027	06/25/2036	Common Stock	26,000	$0	26,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

	/s/ Sam Martin, attorney-in-fact for Keith L. Brownlie	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Celldex (CLDX) director Keith L. Brownlie receive in this Form 4?

Keith L. Brownlie received a grant of 26,000 non-qualified stock options from Celldex. These options were awarded under the 2021 Omnibus Equity Incentive Plan and represent compensation, not an open-market purchase or sale of existing Celldex common shares.

What is the exercise price of Keith Brownlie’s new Celldex (CLDX) stock options?

The granted options have an exercise price of $34.09 per share. This means Brownlie can buy Celldex common stock at $34.09 using these options once they become exercisable, regardless of the market price at that future time.

When do Keith Brownlie’s Celldex (CLDX) stock options become exercisable and when do they expire?

The options become exercisable on June 25, 2027 and expire on June 25, 2036. After the expiration date, any unexercised options will lapse, and Brownlie will no longer be able to purchase shares under this specific grant.

How many Celldex (CLDX) options does Keith Brownlie hold after this grant?

After this transaction, Brownlie is shown as holding 26,000 derivative securities of this option type. This figure reflects the newly granted non-qualified stock options reported in the Form 4 and represents his position from this specific award.

Under which plan were Keith Brownlie’s Celldex (CLDX) options granted?

The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan is used by the company to award equity-based compensation, such as stock options, to directors, officers, employees, and other eligible participants to align their interests with shareholders.